Legal Disclaimers 2023 EyePoint Pharmaceuticals, Inc. All Rights Reserved. Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995
Sunday, December 31, 2023 1 min read
Key Takeaway: EyePoint Pharmaceuticals is currently conducting a Phase 2 clinical trial called the VERONA trial, which focuses on the efficacy and safety of EYP-1901 for patients with diabetic macular edema (DME). This open-label trial evaluates two dosing regimens of EYP-1901 compared to aflibercept. The primary endpoint is the time to the need for a supplemental anti-VEGF injection up to 24 weeks. Topline data is expected in the first quarter of 2025, which will help inform future clinical studies.
Market Sentiment Analysis
POSITIVE FACTORS
EYP-1901 is undergoing a Phase 2 clinical trial, which indicates progress.
The trial aims to collect important safety and efficacy data for DME patients.
Topline data anticipated in Q1 2025 suggests a timeline for future developments.
Full Press Release Details
Phase 2 VERONA Clinical Trial is a Randomized, Open-Label, Aflibercept Controlled Trial with a Single EYP-1901 Injection EYP-1901 dosing Visit Scheduled aflibercept injection Sham injection EYP-1901 low dose (n=10) EYP-1901 high dose (n=10) Aflibercept 2mg single injection (n=5) Supplemental Anti-VEGF injection based on prespecified criteria Potential 6-month treatment in previously treated DME patients Objectives: Evaluate the safety and efficacy of two doses of EYP-1901 in the DME patient population Collect dose-ranging data to inform future clinical trials Primary endpoint: time to supplemental anti-VEGF injection up to week 24 Secondary endpoints: Change in BCVA vs. aflibercept control, stable anatomical outcome as measured by OCT, DRSS over time Primary endpoint -D28 to -D7 D1 W4 W8 W12 W16 W20 W24 First patient dosed; topline data anticipated in Q1 2025
Frequently Asked Questions
What is the Phase 2 VERONA Clinical Trial testing?
The trial evaluates the safety and efficacy of two doses of EYP-1901 in DME patients.
What is the primary endpoint of the trial?
The primary endpoint is the time to supplemental anti-VEGF injection up to week 24.
How many doses of EYP-1901 are being tested?
Two doses of EYP-1901 are being evaluated in the trial.
When is topline data expected from the trial?
Topline data from the trial is anticipated in Q1 2025.
What is the focus of the secondary endpoints?
Secondary endpoints include BCVA changes, anatomical outcomes, and DRSS over time.